CHING-HUNG LINZahid, MuhammadMuhammadZahidWEN-HUNG KUOHu, Fu-ChangFu-ChangHuMING-YANG WANGI-CHUN CHENBeseler, Cheryl LCheryl LBeselerMondal, BodhisattwaBodhisattwaMondalYEN-SHEN LURogan, Eleanor GEleanor GRoganANN-LII CHENG2023-05-092023-05-092023-03-011940-62071940-6215https://scholars.lib.ntu.edu.tw/handle/123456789/630921The incidence of breast cancer among premenopausal women has been increasing rapidly in recent decades in East Asia. This case-control study investigated whether estrogen-DNA adducts were associated with breast cancer risk in Taiwan. The control group (n = 146) comprised healthy female volunteers and women with non-proliferative breast disease. The case group (n = 221) comprised women either with proliferative benign breast disease or breast cancer. The ratios of estrogen-DNA adducts to their respective metabolites and conjugates in plasma were analyzed using ultraperformance LC/MS-MS. The SNPs of CYP1A1, CYP1B1, and COMT were genotyped. Logistic regression model was used to compare the estrogen-DNA adduct ratios between the two groups. The estrogen-DNA adduct ratio in the case group was significantly higher than that in the control group (median ratio: 58.52 vs. 29.36, P = 0.004). A multiple logistic regression model demonstrated that a unit increase in the natural log of the estrogen-DNA adduct ratio in premenopausal women was a significant predictor of breast cancer risk, with an estimated hazard ratio of 1.718 (1.444-2.046, P < 0.001). However, the CYP1A1, CYP1B1, and COMT SNPs were not associated with the estrogen-DNA adduct ratios. In conclusion, plasma estrogen-DNA adduct ratio was associated with the presence of breast cancer or proliferating benign breast disease in premenopausal women in Taiwan.enjournal article10.1158/1940-6207.CAPR-22-0415365174632-s2.0-85149154464https://api.elsevier.com/content/abstract/scopus_id/85149154464